 Zacks Investment Research lowered shares of Beyondspring NASDAQ:BYSI from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Companys lead product consists of into a ... 